

Table SI. Summary of patient characteristics

Pat.	Sex/age, years	Facial manifestation	Digital clubbing	Arthralgia	X-rays	Facial wrinkle scale	
						Before treatment	4 weeks after treatment
1	M/22	Thickened skin with glabellar furrows	Yes	Yes	Subperiosteal new bone formation bilaterally in the extremities	3	1
						2	1
						2	1
						2	1
2	M/28	Significant thickened skin on the forehead and glabellar region and eyelid	Yes	Yes	Periosteal changes and enlargement of the joints	3	2
3	M/26	Thickened skin on the forehead and glabellar region and acne	Yes	Yes	Periostosis of the long bones	3	2




Fig. S1. Injection sites and doses for patients with PDP. (a) BTX-A was injected into procerus muscle (single spot, 5U), the *corrugator supercilii* muscles (2 spots, medially at the site of their attachment to the bone using 5U each, and laterally at the skin insertion sites using 4U each) for patient 1. (b) The procerus muscle (single spot, 10U), the *corrugator supercilii* muscles (2 spots, medially at the site of their attachment to the bone using 7U each and laterally at the skin insertion sites using 5U each), forehead (7 intradermal injections along the furrows using 3U each) and the lateral tail of each eyebrow (3U each) for patient 2. (c) Sites and doses in the glabellar region were the same as case 1, 5 intradermal injections along the forehead were given using 2U each for patient 3.